Research Article

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer

Table 1

Ovarian cancer clinical data. A predominance of ovarian serous cystadenocarcinoma with malignant ascites can be observed. Cytoreduction was optimal in 14 patients and suboptimal in 10 patients: only 10 patients were platinum-sensitive, 4 platinum-resistant, and 7 platinum-refractory (all 7 perished during the first year). The majority of patients were discovered in advanced stages.

Platinum-sensitivePlatinum-resistantPlatinum-refractory

Weight (kg)69 ± 1975 ± 2546 ± 21
Body mass index (BMI)27 ± 730 ± 921 ± 4
Ag CA-125 baseline U/mL607.37 ± 183.13915.8 ± 373.87963 ± 363.80
Ag CA-125 final U/mL21.87 ± 6.594211.95 ± 2105.9862.6 ± 25.56
Clinical stage
 IC2
 IIB2
 IIIB21
 IIIC425
 IV12
Histology9 Cystadenocarcinoma3 Cystadenocarcinoma6 Cystadenocarcinoma
1 Undifferentiated1 Endometrioid type1 Endometrioid type
Ascites3 Positive
Malignant ascites7 Positive4 Positive7 Positive
Cytoreduction10 Optimal3 Suboptimal
1 Optimal
7 Suboptimal
Cycle frequency days21215–1 cycle
1–6 cycles
1-2 cycles
Carboplatin (mg)570 ± 109471 ± 187464 ± 124
Paclitaxel (mg)300 ± 39273 ± 106254 ± 63
Deceased27